CN109200086A - The preparation method for treating the Caulis Spatholobi tablet of oophoroma - Google Patents
The preparation method for treating the Caulis Spatholobi tablet of oophoroma Download PDFInfo
- Publication number
- CN109200086A CN109200086A CN201811190649.9A CN201811190649A CN109200086A CN 109200086 A CN109200086 A CN 109200086A CN 201811190649 A CN201811190649 A CN 201811190649A CN 109200086 A CN109200086 A CN 109200086A
- Authority
- CN
- China
- Prior art keywords
- caulis spatholobi
- mass fraction
- weight
- tablet
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/486—Millettia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a kind of preparation methods of Caulis Spatholobi tablet for treating oophoroma, the following steps are included: Step 1: the rattan for choosing Caulis Spatholobi is sliced to obtain sheet Caulis Spatholobi, carry out sofening treatment, it is added in extractor successively with extractant, the ethanol water refluxing extraction that mass fraction is 80%, extracting solution is recovered under reduced pressure to no alcohol taste, adjusts pH, extraction, concentration, obtains concentrate；Step 2: upper D101 macroporous absorbent resin after concentrate is diluted collects 95% ethanol elution solution, recycles ethyl alcohol, be concentrated into the medicinal extract that relative density is 1.08 at 80 DEG C successively with water, the ethanol elution that mass fraction is 40% and 95%；Step 3: medicinal extract is pelletized, tabletting is coated with coating solution to get Caulis Spatholobi tablet.The present invention has the beneficial effect for improving human ovarian cancer HO8910 cell growth inhibition rate.
Description
Technical field
The present invention relates to ovarian cancer fields.It is more particularly related to a kind of Caulis Spatholobi for treating oophoroma
The preparation method of tablet.
Background technique
Malignant tumor of ovary (oophoroma) accounts for 2.4~6.5% in women common cancer, in female reproductive system cancer
The 3rd is accounted in tumor, is inferior to cervical carcinoma and carcinoma of corpus uteri.In recent years, it due to the prevention and treatment to cervical carcinoma and carcinoma of corpus uteri, achieves certain
Effect, and it is relatively small to produce effects in terms of prevention and treatment in relation to oophoroma, so oophoroma is to make in female genital system carcinoma
At a kind of highest tumour of the cause of death, doctor trained in Western medicine generally uses operative treatment, but tumour and metastatic lesion are difficult to completely remove, because
This, prepares new ovarian cancer resistance tumour medicine, provides more selections for the treatment of oophoroma tumor disease, is desirably to obtain curative effect
Better types of drugs.
Summary of the invention
It is an object of the invention to solve at least the above problems, and provide the advantages of at least will be described later.
It is a still further object of the present invention to provide a kind of preparation methods of Caulis Spatholobi tablet for treating oophoroma, improve ovum
The inhibiting rate that nest cancer HO8910 cancer cell increases.
In order to realize these purposes and other advantages according to the present invention, a kind of Caulis Spatholobi piece for treating oophoroma is provided
The preparation method of agent, comprising the following steps:
Step 1: choosing the rattan of Caulis Spatholobi, branches and leaves are removed, sheet Caulis Spatholobi is sliced to obtain, takes sheet Caulis Spatholobi, cellulose
Enzyme, protease, citric acid, sucrose ester, salt, water are mixed by weight 100:0.2:0.1:0.2:0.5:1:500, heating
To 45~50 DEG C, 2.5~3.5h is digested, filter residue I is filtered to take in enzyme deactivation, and filter residue I is added in extractor, is mentioned with extractant reflux
2h is taken, filtrate I and filter residue II are filtered to take, the ethanol water refluxing extraction 4h that mass fraction is 80% is added into filter residue II,
Filtrate II is filtered to take, merging filtrate I and filtrate II obtain filtrate III, and ethyl alcohol is recovered under reduced pressure to filtrate III without alcohol taste, quality point is added
The salt acid for adjusting pH that number is 5~10% is extracted with ethyl acetate to 5.0~6.0, ethyl acetate layer is taken to be concentrated, obtained
Concentrate, wherein extractant is obtained by mixing by ethyl alcohol, ethyl acetate, water, sulphite by weight 40:40:19:1；
Step 2: D101 macroporous absorbent resin is packed into glass column using wet process than the ratio for 1:7~9 according to diameter height
In, concentrate is diluted with 3~4 times of water, diluted concentrate is adsorbed with D101 macroporous absorbent resin, with 5~8 times of glass columns
Long-pending water elution, then with the mass fraction of the eluant, eluent of 4~6 times of glass column volumes, 6~8 times of glass column volumes be successively 40%
Ethanol water, the ethanol water that the mass fraction of 8~10 times of glass column volumes is 95% eluted, collect quality point
Number for 95% ethanol water elution solution, be concentrated into the medicinal extract that relative density at 80 DEG C is 1.08, wherein eluant, eluent by
Methylene chloride, acetone, n-butanol are obtained by mixing by weight 1:3:7；
Step 3: by medicinal extract and the starch of 1 times of weight, the dextrin of 0.8 times of weight, 0.5 times of weight microcrystalline cellulose,
The magnesium stearate mixed pelletization of 0.05~0.08 times of weight, tabletting are coated with coating solution to get Caulis Spatholobi tablet, wherein
Coating solution is obtained by mixing by white granulated sugar, talcum powder, triethyl citrate, the cellulose acetate melted by weight 20:1:3:1.
Preferably, the weight ratio of filter residue I and extractant is 1:3~5 in step 1.
Preferably, the weight ratio for the ethanol water that filter residue II and mass fraction are 80% in step 1 is 1:6~8.
Preferably, the volume ratio of diluted concentrate and D101 macroporous absorbent resin is 1:2~3 in step 2.
Preferably, the flow velocity of the water elution in step 2 is 1.5BV/h.
Preferably, the ethanol water that the flow velocity of eluent is 1.0BV/h in step 2, mass fraction is 40%
The flow velocity for the ethanol water elution that the flow velocity of elution is 1.2BV/h, mass fraction is 95% is 0.8BV/h.
The present invention is include at least the following beneficial effects:
The first, take sheet Caulis Spatholobi, cellulase, protease, citric acid, sucrose ester, salt, water by weight 100:
0.2:0.1:0.2:0.5:1:500 is mixed, and is warming up to 45~50 DEG C, digests 2.5~3.5h, plays the effect of softening Caulis Spatholobi
Fruit is successively extracted using extractant, ethanol water conducive to the extraction for inhibiting cancer cell effective component, improves Caulis Spatholobi
Inhibit the recovery rate of the effective component of cancer cell；
The second, D101 macroporous absorbent resin is fitted into glass column than the ratio for 1:7~9 using wet process according to diameter height,
Concentrate is diluted with 3~4 times of water, diluted concentrate is adsorbed with D101 macroporous absorbent resin, with 5~8 times of glass column volumes
Water elution, then with the mass fraction of the eluant, eluent of 4~6 times of glass column volumes, 6~8 times of glass column volumes be successively 40%
Ethanol water, the ethanol water that the mass fraction of 8~10 times of glass column volumes is 95% are eluted, and mass fraction is collected
For the elution solution of 95% ethanol water, is conducive to the content for improving anticancer active constituent in Millettia extract, improves
Cell inhibitory effect effect to human ovarian cancer HO8910 cell.
Further advantage, target and feature of the invention will be partially reflected by the following instructions, and part will also be by this
The research and practice of invention and be understood by the person skilled in the art.
Specific embodiment
The present invention will be further described in detail below with reference to the embodiments, to enable those skilled in the art referring to specification
Text can be implemented accordingly.
It should be noted that experimental method described in following embodiments is unless otherwise specified conventional method, institute
Reagent and material are stated, unless otherwise specified, is commercially obtained.
<embodiment 1>
The preparation method for treating the Caulis Spatholobi tablet of oophoroma, comprising the following steps:
Step 1: choosing the rattan of Caulis Spatholobi, branches and leaves are removed, sheet Caulis Spatholobi is sliced to obtain, takes sheet Caulis Spatholobi, cellulose
Enzyme, protease, citric acid, sucrose ester, salt, water are mixed by weight 100:0.2:0.1:0.2:0.5:1:500, heating
To 45 DEG C, 2.5h is digested, filter residue I is filtered to take in enzyme deactivation, filter residue I is added in extractor, with extractant refluxing extraction 2h, filtering
Filtrate I and filter residue II are taken, the ethanol water refluxing extraction 4h that mass fraction is 80% is added into filter residue II, filters to take filtrate
II, merging filtrate I and filtrate II obtain filtrate III, and ethyl alcohol is recovered under reduced pressure to filtrate III without alcohol taste, the salt that mass fraction is 5% is added
Acid for adjusting pH is extracted with ethyl acetate to 6.0, ethyl acetate layer is taken to be concentrated, obtain concentrate, wherein extractant by
Ethyl alcohol, ethyl acetate, water, sulphite are obtained by mixing by weight 40:40:19:1；
Step 2: D101 macroporous absorbent resin is fitted into glass column than the ratio for 1:7 using wet process according to diameter height, use
3 times of water dilutes concentrate, adsorbs diluted concentrate with D101 macroporous absorbent resin, with the water elution of 5 times of glass column volumes,
Again successively with the mass fraction of the eluant, eluent of 4 times of glass column volumes, 6 times of glass column volumes be 40% ethanol water, 8 times of glass
The ethanol water that the mass fraction of glass column volume is 95% is eluted, and the ethanol water that mass fraction is 95% is collected
Solution is eluted, is concentrated into the medicinal extract that relative density is 1.08 at 80 DEG C, wherein eluant, eluent is pressed by methylene chloride, acetone, n-butanol
Weight ratio 1:3:7 is obtained by mixing；
Step 3: by medicinal extract and the starch of 1 times of weight, the dextrin of 0.8 times of weight, 0.5 times of weight microcrystalline cellulose,
The magnesium stearate mixed pelletization of 0.05~0.08 times of weight, tabletting are coated with coating solution to get Caulis Spatholobi tablet, wherein
Coating solution is obtained by mixing by white granulated sugar, talcum powder, triethyl citrate, the cellulose acetate melted by weight 20:1:3:1.
The weight ratio of filter residue I and extractant is 1:3 in step 1.
The weight ratio for the ethanol water that filter residue II and mass fraction are 80% in step 1 is 1:6.
The volume ratio of diluted concentrate and D101 macroporous absorbent resin is 1:2 in step 2.
The flow velocity of water elution in step 2 is 1.5BV/h.
The stream for the ethanol water elution that the flow velocity of eluent is 1.0BV/h in step 2, mass fraction is 40%
The flow velocity for the ethanol water elution that speed is 1.2BV/h, mass fraction is 95% is 0.8BV/h.
<embodiment 2>
The preparation method for treating the Caulis Spatholobi tablet of oophoroma, comprising the following steps:
Step 1: choosing the rattan of Caulis Spatholobi, branches and leaves are removed, sheet Caulis Spatholobi is sliced to obtain, takes sheet Caulis Spatholobi, cellulose
Enzyme, protease, citric acid, sucrose ester, salt, water are mixed by weight 100:0.2:0.1:0.2:0.5:1:500, heating
To 50 DEG C, 3.5h is digested, filter residue I is filtered to take in enzyme deactivation, filter residue I is added in extractor, with extractant refluxing extraction 2h, filtering
Filtrate I and filter residue II are taken, the ethanol water refluxing extraction 4h that mass fraction is 80% is added into filter residue II, filters to take filtrate
II, merging filtrate I and filtrate II obtain filtrate III, ethyl alcohol are recovered under reduced pressure to filtrate III without alcohol taste, it is 10% that mass fraction, which is added,
Salt acid for adjusting pH is extracted with ethyl acetate to 5.0, ethyl acetate layer is taken to be concentrated, obtain concentrate, wherein extractant
It is obtained by mixing by ethyl alcohol, ethyl acetate, water, sulphite by weight 40:40:19:1；
Step 2: D101 macroporous absorbent resin is fitted into glass column than the ratio for 1:9 using wet process according to diameter height, use
4 times of water dilutes concentrate, adsorbs diluted concentrate with D101 macroporous absorbent resin, with the water elution of 8 times of glass column volumes,
Again successively with the mass fraction of the eluant, eluent of 6 times of glass column volumes, 8 times of glass column volumes be 40% ethanol water, 10 times
The ethanol water that the mass fraction of glass column volume is 95% is eluted, and the ethanol water that mass fraction is 95% is collected
Elution solution, be concentrated into the medicinal extract that relative density at 80 DEG C is 1.08, wherein eluant, eluent is by methylene chloride, acetone, n-butanol
It is obtained by mixing by weight 1:3:7；
Step 3: by medicinal extract and the starch of 1 times of weight, the dextrin of 0.8 times of weight, 0.5 times of weight microcrystalline cellulose,
The magnesium stearate mixed pelletization of 0.05~0.08 times of weight, tabletting are coated with coating solution to get Caulis Spatholobi tablet, wherein
Coating solution is obtained by mixing by white granulated sugar, talcum powder, triethyl citrate, the cellulose acetate melted by weight 20:1:3:1.
The weight ratio of filter residue I and extractant is 1:5, the second that filter residue II and mass fraction are 80% in step 1 in step 1
The weight ratio of alcohol solution is 1:8.
The volume ratio of diluted concentrate and D101 macroporous absorbent resin is 1:3 in step 2, the water elution in step 2
Flow velocity be 1.5BV/h, in step 2 the flow velocity of eluent be 1.0BV/h, the ethanol water that mass fraction is 40%
The flow velocity for the ethanol water elution that the flow velocity of elution is 1.2BV/h, mass fraction is 95% is 0.8BV/h.
<embodiment 3>
The preparation method for treating the Caulis Spatholobi tablet of oophoroma, comprising the following steps:
Step 1: choosing the rattan of Caulis Spatholobi, branches and leaves are removed, sheet Caulis Spatholobi is sliced to obtain, takes sheet Caulis Spatholobi, cellulose
Enzyme, protease, citric acid, sucrose ester, salt, water are mixed by weight 100:0.2:0.1:0.2:0.5:1:500, heating
To 48 DEG C, 3h is digested, filter residue I is filtered to take in enzyme deactivation, and filter residue I is added in extractor, with extractant refluxing extraction 2h, is filtered to take
The ethanol water refluxing extraction 4h that mass fraction is 80% is added into filter residue II, filters to take filtrate for filtrate I and filter residue II
II, merging filtrate I and filtrate II obtain filtrate III, and ethyl alcohol is recovered under reduced pressure to filtrate III without alcohol taste, the salt that mass fraction is 7% is added
Acid for adjusting pH is extracted with ethyl acetate to 5.5, ethyl acetate layer is taken to be concentrated, obtain concentrate, wherein extractant by
Ethyl alcohol, ethyl acetate, water, sulphite are obtained by mixing by weight 40:40:19:1；
Step 2: D101 macroporous absorbent resin is fitted into glass column than the ratio for 1:8 using wet process according to diameter height, use
3.5 times of water dilutes concentrate, diluted concentrate is adsorbed with D101 macroporous absorbent resin, with the washing of 6 times of glass column volumes
It is de-, then successively with the mass fraction of the eluant, eluent of 5 times of glass column volumes, 7 times of glass column volumes for 40% ethanol water, 9
The ethanol water that the mass fraction of times glass column volume is 95% is eluted, and it is water-soluble to collect the ethyl alcohol that mass fraction is 95%
The elution solution of liquid is concentrated into the medicinal extract that relative density is 1.08 at 80 DEG C, wherein eluant, eluent is by methylene chloride, acetone, positive fourth
Alcohol is obtained by mixing by weight 1:3:7；
Step 3: by medicinal extract and the starch of 1 times of weight, the dextrin of 0.8 times of weight, 0.5 times of weight microcrystalline cellulose,
The magnesium stearate mixed pelletization of 0.05~0.08 times of weight, tabletting are coated with coating solution to get Caulis Spatholobi tablet, wherein
Coating solution is obtained by mixing by white granulated sugar, talcum powder, triethyl citrate, the cellulose acetate melted by weight 20:1:3:1.
The weight ratio of filter residue I and extractant is 1:4 in step 1.
The weight ratio for the ethanol water that filter residue II and mass fraction are 80% in step 1 is 1:7.
The volume ratio of diluted concentrate and D101 macroporous absorbent resin is 1:2.5 in step 2.
The flow velocity of water elution in step 2 is 1.5BV/h.
The stream for the ethanol water elution that the flow velocity of eluent is 1.0BV/h in step 2, mass fraction is 40%
The flow velocity for the ethanol water elution that speed is 1.2BV/h, mass fraction is 95% is 0.8BV/h.
<comparative example 1>
The preparation method of the Caulis Spatholobi tablet of oophoroma is treated with embodiment 3, wherein unlike, step 1 are as follows: choose
The rattan of Caulis Spatholobi removes branches and leaves, is sliced to obtain sheet Caulis Spatholobi, and the ethanol water that mass fraction is 80% is added to sheet Caulis Spatholobi
Solution refluxing extraction 4h, filters to take filtrate I and filter residue I, and the ethanol water that mass fraction is 80% is added into filter residue I and flows back
4h is extracted, filtrate II is filtered to take, merging filtrate I and filtrate II obtain filtrate III, ethyl alcohol is recovered under reduced pressure to filtrate III without alcohol taste, obtains dense
Contracting liquid；
Step 2 are as follows: adsorb concentrate using D101 macroporous absorbent resin, successively with the water of 4 times of glass column volumes, 5 times
The ethyl alcohol that the mass fraction of glass column volume is 45% ethanol water, the mass fraction of 6 times of glass column volumes is 85% is water-soluble
Liquid is eluted, and collects the elution solution for the ethanol water that mass fraction is 95%, being concentrated into relative density at 80 DEG C is
1.12 medicinal extract.
<comparative example 2>
The preparation method of the Caulis Spatholobi tablet of oophoroma is treated with embodiment 3, wherein unlike, step 1 are as follows: choose
The rattan of Caulis Spatholobi removes branches and leaves, is sliced to obtain sheet Caulis Spatholobi, and the ethanol water that mass fraction is 80% is added to sheet Caulis Spatholobi
Solution refluxing extraction 4h, filters to take filtrate I and filter residue I, and the ethanol water that mass fraction is 80% is added into filter residue I and flows back
4h is extracted, filtrate II is filtered to take, merging filtrate I and filtrate II obtain filtrate III, ethyl alcohol is recovered under reduced pressure to filtrate III without alcohol taste, obtains dense
Contracting liquid.
<inhibitory effect evaluation test of the Caulis Spatholobi tablet to human ovarian cancer HO8910 cell in-vitro growth>
Material: human ovarian cancer HO8910 cell, calf serum (FBS), RPMI1640 culture solution, Methyl thiazoly tetrazolium assay
(MTT), mass fraction be 0.25% trypsase, dimethyl sulfoxide (DMSO), Examples 1 to 3 and comparative example 1~2 chicken blood
Rattan tablet
HO8910 cell culture: cell HO8910 is placed in penicillin containing 100IU/ml, 100IU/ml streptomysin, quality point
In the FBS RPMI1640 culture solution that number is 10%, in 37 DEG C, 5%CO2, routine culture under conditions of saturated humidity, culture is extremely
It is paved with after bottom of bottle with the tryptic digestive juice vitellophag containing 0.25% and by 1.0 × 105/ ml sub-bottle, 3d passage are primary.
Cell growth inhibition assay (mtt assay): logarithmic growth phase HO8910 cell is broken into trypsin digestion after-blow
Single cell suspension (1.0 × 105/ ml), take 100 μ L to be inoculated in 96 well culture plates respectively, cell is adherent for 24 hours for culture, is added and crushes
Examples 1 to 3 and comparative example 1~2 in Caulis Spatholobi tablet, if 8 multiple holes, while using physiological saline as blank control
Group cultivates 72h, and adding 20 μ L concentration is the MTT liquid of 5mg/ml, and 37 DEG C of incubation 4h abandon training liquid, add 200 μ L DMSO, room after centrifugation
Temperature is lower to vibrate 10min, measures light absorption value (OD) in 570nm after completely dissolution, calculates the inhibiting rate grown to HO8910 cell, knot
Structure is as shown in table 1.
| Embodiment 1 | Embodiment 2 | Embodiment 3 | Comparative example 1 | Comparative example 2 | |
| Inhibiting rate (%) | 66.7 | 69.2 | 68.5 | 56.2 | 61.2 |
As shown in Table 1, the Caulis Spatholobi tablet in Examples 1 to 3 is compared with the Caulis Spatholobi tablet in comparative example 1~2 to HO8910
There are good inhibiting effect, comparative examples 2 to have good inhibiting effect, table compared with the Caulis Spatholobi tablet of comparative example 1 for the growth of cell
The extraction operation of step two in bright comparative example 2 improves the content of anticancer active constituent in Millettia extract.
Although the embodiments of the present invention have been disclosed as above, but its is not only in the description and the implementation listed
With it can be fully applied to various fields suitable for the present invention, for those skilled in the art, can be easily
Realize other modification, therefore without departing from the general concept defined in the claims and the equivalent scope, the present invention is simultaneously unlimited
In specific details and embodiment shown and described herein.
Claims (6)
1. the preparation method for treating the Caulis Spatholobi tablet of oophoroma, which comprises the following steps:
Step 1: choose Caulis Spatholobi rattan, remove branches and leaves, be sliced to obtain sheet Caulis Spatholobi, take sheet Caulis Spatholobi, cellulase,
Protease, citric acid, sucrose ester, salt, water are mixed by weight 100:0.2:0.1:0.2:0.5:1:500, are warming up to
45~50 DEG C, 2.5~3.5h is digested, filter residue I is filtered to take in enzyme deactivation, filter residue I is added in extractor, with extractant refluxing extraction
2h filters to take filtrate I and filter residue II, and the ethanol water refluxing extraction 4h that mass fraction is 80%, mistake are added into filter residue II
Leaching filtrate II, merging filtrate I and filtrate II obtain filtrate III, and ethyl alcohol is recovered under reduced pressure to filtrate III without alcohol taste, mass fraction is added
For 5~10% salt acid for adjusting pH to 5.0~6.0, extracted with ethyl acetate, ethyl acetate layer taken to be concentrated, obtained dense
Contracting liquid, wherein extractant is obtained by mixing by ethyl alcohol, ethyl acetate, water, sulphite by weight 40:40:19:1；
Step 2: D101 macroporous absorbent resin is fitted into glass column than the ratio for 1:7~9 using wet process according to diameter height, with 3
~4 times of water dilutes concentrate, diluted concentrate is adsorbed with D101 macroporous absorbent resin, with the water of 5~8 times of glass column volumes
Elution, then the ethyl alcohol for being successively 40% with the mass fraction of the eluant, eluent of 4~6 times of glass column volumes, 6~8 times of glass column volumes
Aqueous solution, the ethanol water that the mass fraction of 8~10 times of glass column volumes is 95% are eluted, and collecting mass fraction is
The elution solution of 95% ethanol water is concentrated into the medicinal extract that relative density is 1.08 at 80 DEG C, wherein eluant, eluent is by dichloro
Methane, acetone, n-butanol are obtained by mixing by weight 1:3:7；
Step 3: by medicinal extract and the starch of 1 times of weight, the dextrin of 0.8 times of weight, the microcrystalline cellulose of 0.5 times of weight, 0.05~
The magnesium stearate mixed pelletization of 0.08 times of weight, tabletting are coated with coating solution to get Caulis Spatholobi tablet, wherein coating solution
It is obtained by mixing by the white granulated sugar, talcum powder, triethyl citrate, the cellulose acetate that melt by weight 20:1:3:1.
2. the preparation method of the Caulis Spatholobi tablet for the treatment of oophoroma as described in claim 1, which is characterized in that filtered in step 1
The weight ratio of slag I and extractant is 1:3~5.
3. the preparation method of the Caulis Spatholobi tablet for the treatment of oophoroma as described in claim 1, which is characterized in that filtered in step 1
The weight ratio for the ethanol water that slag II and mass fraction are 80% is 1:6~8.
4. the preparation method of the Caulis Spatholobi tablet for the treatment of oophoroma as described in claim 1, which is characterized in that dilute in step 2
The volume ratio of the concentrate and D101 macroporous absorbent resin released is 1:2~3.
5. the preparation method of the Caulis Spatholobi tablet for the treatment of oophoroma as described in claim 1, which is characterized in that in step 2
The flow velocity of water elution is 1.5BV/h.
6. the preparation method of the Caulis Spatholobi tablet for the treatment of oophoroma as described in claim 1, which is characterized in that washed in step 2
The flow velocity for the ethanol water elution that the flow velocity of de- agent elution is 1.0BV/h, mass fraction is 40% is 1.2BV/h, quality is divided
Number is 0.8BV/h for the flow velocity of 95% ethanol water elution.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811190649.9A CN109200086A (en) | 2018-10-12 | 2018-10-12 | The preparation method for treating the Caulis Spatholobi tablet of oophoroma |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811190649.9A CN109200086A (en) | 2018-10-12 | 2018-10-12 | The preparation method for treating the Caulis Spatholobi tablet of oophoroma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109200086A true CN109200086A (en) | 2019-01-15 |
Family
ID=64979782
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811190649.9A Pending CN109200086A (en) | 2018-10-12 | 2018-10-12 | The preparation method for treating the Caulis Spatholobi tablet of oophoroma |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109200086A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1969945A (en) * | 2006-12-01 | 2007-05-30 | 广西中医学院 | Chinese medicinal blood tonic and preparation process thereof |
| CN101849988A (en) * | 2010-05-31 | 2010-10-06 | 广州医药工业研究院 | Millettia extract and preparation method and application thereof |
| CN102579425A (en) * | 2012-01-16 | 2012-07-18 | 陈建萍 | Caulis Spatholobi extract, application thereof and new application of isoliquiritigenin |
-
2018
- 2018-10-12 CN CN201811190649.9A patent/CN109200086A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1969945A (en) * | 2006-12-01 | 2007-05-30 | 广西中医学院 | Chinese medicinal blood tonic and preparation process thereof |
| CN101849988A (en) * | 2010-05-31 | 2010-10-06 | 广州医药工业研究院 | Millettia extract and preparation method and application thereof |
| CN102579425A (en) * | 2012-01-16 | 2012-07-18 | 陈建萍 | Caulis Spatholobi extract, application thereof and new application of isoliquiritigenin |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103601775A (en) | Method for extracting hesperidin from orange peels | |
| CN107118218A (en) | The preparation method and its usage of aristolo-lactam class noval chemical compound | |
| CN101249259A (en) | High content and high activity oral polysaccharide-peptide and preparing method and application of the same | |
| CN101747307A (en) | Glycyrrhizic acid removal glycyrrhiza flavonoid and medicament composition thereof | |
| CN107501356A (en) | A kind of method that rutin is extracted from the sophora bud | |
| CN101804089B (en) | Use of total flavonoids from radix Daphne genkwa in preparing weight-losing hypolipemic drugs | |
| CN108546304A (en) | A method of preparing poly- arabogalactan aldehydic acid using dried orange peel | |
| CN106138130B (en) | Mango seed flavone extract and preparation method thereof | |
| CN105816597B (en) | A kind of Chinese medicine pre-mixing agent and preparation method thereof for preventing and treating prevention of sow constipation | |
| CN108486206A (en) | A kind of purple sweet potato cyanidin synthesis extracting method | |
| CN109200086A (en) | The preparation method for treating the Caulis Spatholobi tablet of oophoroma | |
| CN104784252B (en) | The preparation method and applications of total alkaloid from sophora flavescens ait extract | |
| CN102935104A (en) | Maackia amurensis total flavone extract, as well as preparation method and application thereof | |
| CN103893412B (en) | A kind of antitumor beautyberry extract and its production and use | |
| CN108276467A (en) | A kind of Tea Saponin and its extraction process and application | |
| CN115487225A (en) | Preparation method of sophora flower bud extract | |
| CN111018929B (en) | Process for extracting and separating isocoryzanol | |
| CN110882246B (en) | Extraction method and application of coptis alkaloid with different biological activities | |
| CN110144015B (en) | Method for synchronously extracting and purifying ganoderan, ganoderma triterpenic acid and amino acid | |
| CN110302244A (en) | A kind of application of the astragalus polyose joint mescenchymal stem cell in preparation treatment end-age cirrhosis drug | |
| CN108653369A (en) | A kind of preparation method of honeysuckle extractive of general flavone and its application in honey refines emblic loquat leaf extract | |
| CN107412607B (en) | Asparagus capsule and preparation method thereof | |
| CN107823247A (en) | Application of the beans taro stem tuber ethanol extract in liver cell lipidosis is reduced | |
| CN108558645A (en) | The method that crocin is extracted from cape jasmine | |
| CN102319273A (en) | Salicornia biggelowii Torr. active total saponin extract, its preparation method and its purpose of losing weight |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190115 |
|
| RJ01 | Rejection of invention patent application after publication |